Liquidia sells Yutrepia, a treprostinil dry-powder inhaler for PAH and PH-ILD that has spent the last twelve months taking durable share from UTHR's nebulized Tyvaso franchise. The stock has run +218% YoY and +43% in the last month on Q1 2026 results that confirmed the share-capture thesis: $129.9M revenue, $52.9M net income, $222.8M cash, fully self-funding. We looked at this on the 10-Q drop expecting a routine quarterly read. The interesting finding wasn't in the filing.

What the filing says

The 10-Q ratifies the 8-K numbers but adds three layers the press release didn't carry. First, the litigation surface widened: four active UTHR proceedings, the '327 patent decision pending from Judge Andrews (post-trial, could drop any day), the trade secret trial set for January 2027 (LQDA's MSJ was DENIED July 2025 — UTHR's claims survived), and UTHR's relief sought includes co-ownership of LQDA's '494 patent. Second, three new competitive threats were disclosed in risk factors: UTHR's Tresmi soft mist inhaler (announced February 2026, 505(b)(1) NDA filing planned 2026), Insmed's TPIP (Phase 3 enrolling), and ralinepag oral (positive Phase 3 March 2026). Third, the Q1 91.5% gross margin is artificially elevated — pre-launch R&D-expensed inventory has fully sold through; future COGS will reflect full manufacturing cost.

Cross-ticker reading hardens these threats. UTHR's own Q1 2026 call disclosed, verbatim, "TYVASO prescriptions approximately same level Yutrepia," and they booked a $26.8M Tyvaso DPI inventory writedown — they overcommitted on MannKind DPI volume because Yutrepia took more share than they expected. The same UTHR 10-Q clarifies the '494 stay is structurally tied to the January 2027 trade secret trial, not a near-term procedural pause: LQDA's '494 counterclaim is contingent on the trade secret outcome where the existential downside lives. UTHR's pipeline reload is broader than LQDA's risk factors implied — three next-generation prostacyclin/IP-agonist programs (ralinepag oral, raldpi DPI, Triple Combo), Tresmi, plus Treprostinil-Iloprost SMI combo. TETON-1 IPF data came in at +130.1 mL FVC (p<0.0001), stronger than TETON-2; UTHR is seeking priority review, and if approved Q1-Q2 2027 the 7-year orphan exclusivity blocks Yutrepia from IPF through ≈2034.

What the market thinks

Consensus PT $43, with sell-side dispersed $32-$67. H.C. Wainwright $67 and Wells Fargo $62 on the bull side; Scotia $37, Raymond James $33, Needham $32 on the skeptical side. ATM IV 83.8% on the 62-day expiry — the market is pricing significant near-term variance. RSI 88, IV rank 92, max pain $40 (-30% from spot).

Decomposing the factor surface: ≈92% idiosyncratic variance (β to SPX 0.42, β to XBI ≈0.7). Forward 12-24mo idio variance allocates roughly 27% to '327 ruling, 22% to trade secret trial, 18% to Yutrepia commercial trajectory, 12% to UTHR pipeline reload, 7% to IPF orphan blockade. Probability-weighted: E[forward price] ≈ $42 — the consensus PT confirms this math. Bull PTs imply joint probability of all-favorable factor outcomes near 0.55-0.65; the actual joint probability we estimate is ≈0.20.

Why the gap exists

The bull case multiplies favorable states across independent factors without compounding correctly. Wainwright's $67 is consistent with each individual factor resolving 75-80% favorable; that math breaks when you compute the joint distribution. Sell-side coverage is bifurcated because the analyst community is collectively pricing one factor at a time — '327 favorable case dominates bull models, trade secret existential tail dominates bear models, neither side stacks both.

Insiders are stacking both. In the 30 days surrounding this filing: CEO Roger Jeffs sold four times for $11.8M total, Director Stephen Bloch dumped $16M of stock on May 11 — the same day the 10-Q dropped — and COO Michael Kaseta exercised and sold $5.7M on April 15. Zero Code P (open-market purchase) Form 4s. Five separate insiders selling into the parabola at $42-$53 range. The people best positioned to assess the joint distribution are voting with their book.

Risks (to the bear read)

1. '327 ruling clean LQDA win plus Q2 beat — would compress near-term variance, force shorts to cover (13.9% SI, 9.4 DTC), and validate the bull narrative. Cleanest single event that breaks the structured bear.
2. UTHR delays Tresmi NDA or ralinepag NDA past Q4 2026 — compresses the 2027 competitive cluster, gives Yutrepia an extra year of clean runway.
3. Trade secret favorable settlement — collapses the existential tail and lifts the overhang; equity could re-rate +20-30%.
4. Sotatercept sequencing materializes faster than expected (cuts both ways — bear for prostacyclins broadly, but accelerates LQDA's structural decline rather than UTHR's).

Catalysts

What would change our mind

• UTHR drops or settles the trade secret case in LQDA's favor with no patent assignment
• Judge Andrews delivers a clean LQDA win on '327 AND LQDA Q2 print sustains sequential growth AND UTHR delays Tresmi NDA past 2027
• INSM TPIP Phase 3 misses primary endpoint (compresses 2028-2030 competitive surface)
• Multiple Form 4 P-codes (open-market purchases) by C-suite insiders post any pullback

Bottom line

The math agrees with consensus. The marginal buyer at $57.42 is pricing closer to bull dispersion than to consensus. Insiders are pricing closer to consensus than to bull dispersion. The 2027 binary cluster (trade secret trial + ralinepag launch + Tresmi launch + TETON IPF approval) is where the joint distribution materializes.

Evidence